Amide compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same
The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.
1. A compound represented by Formula (I), or a salt thereof:
wherein m represents an integer of 0 to 2, and n represents an integer of 0 to 1, provided that 0≤m+n≤2;
R 1 represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted amino group;
R 2 represents an optionally substituted fluorenyl group, a substituted naphthyl group, or an optionally substituted group represented by any one of the following structures:
R 3 represents 0 to 7 identical or different substituents attached to the naphthyl group; and
X represents a single bond, —CH 2 — group, or —NH— group.
2. The compound or a salt thereof according to claim 1 , wherein m is 1 and n is 0.
3. The compound or a salt thereof according to claim 1 , wherein R 1 represents a hydrogen atom.
4. The compound or a salt thereof according to claim 1 , wherein X represents a single bond.
5. A Pin1 inhibitor comprising a compound represented by Formula (I) or a salt thereof:
wherein m represents an integer of 0 to 2, and n represents an integer of 0 to 1, provided that 0≤m+n≤2;
R 1 represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted amino group;
R 2 represents an optionally substituted fluorenyl group, a substituted naphthyl group, or an optionally substituted group represented by any one of the following structures:
R 3 represents 0 to 7 identical or different substituents attached to the naphthyl group; and
X represents a single bond, —CH 2 — group, or —NH— group.
6. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.
7. A therapeutic agent for the treatment of an inflammatory disease associated with fibrosis, comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient:
wherein m represents an integer of 0 to 2, and n represents an integer of 0 to 1, provided that 0≤m+n≤2;
R 1 represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted amino group;
R 2 represents an optionally substituted fluorenyl group, a substituted naphthyl group, or an optionally substituted group represented by any one of the following structures:
R 3 represents 0 to 7 identical or different substituents attached to the naphthyl group; and
X represents a single bond, —CH 2 — group, or —NH— group.
8. The therapeutic agent according to claim 7 , further comprising an active ingredient of at least one additional drug for the treatment of the inflammatory disease associated with fibrosis.
9. A method of treating an inflammatory disease associated with fibrosis, comprising administering the therapeutic agent according to claim 7 , in combination with at least one additional drug for the treatment of the inflammatory disease associated with fibrosis.
10. A method of preparing a medicament for the treatment of an inflammatory disease associated with fibrosis, comprising combining a pharmaceutically acceptable carrier and a therapeutic amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1 .
11. A method of treating an inflammatory disease associated with fibrosis, comprising administering the compound or a pharmaceutically acceptable salt thereof according to claim 1 to a patient in need thereof.
12. A therapeutic agent for the treatment of cancer, comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient:
wherein m represents an integer of 0 to 2, and n represents an integer of 0 to 1, provided that 0≤m+n≤2;
R 1 represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted amino group;
R 2 represents an optionally substituted fluorenyl group, a substituted naphthyl group, or an optionally substituted group represented by any one of the following structures:
R 3 represents 0 to 7 identical or different substituents attached to the naphthyl group; and
X represents a single bond, —CH 2 — group, or —NH— group.
13. The therapeutic agent according to claim 12 , wherein the cancer is colon cancer or prostate cancer.
14. The therapeutic agent according to claim 12 , further comprising an active ingredient of at least one additional drug for the treatment of cancer.
15. A method of treating cancer, comprising administering the therapeutic agent according to claim 12 , in combination with at least one additional drug for the treatment of cancer.
16. A method of preparing a medicament for the treatment of cancer, comprising combining a pharmaceutically acceptable carrier and a therapeutic amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1 .
17. A method of treating cancer, comprising administering the compound or a pharmaceutically acceptable salt thereof according to claim 1 to a patient in need thereof.
18. A therapeutic agent for the treatment of obesity, comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient:
wherein m represents an integer of 0 to 2, and n represents an integer of 0 to 1, provided that 0≤m+n≤2;
R 1 represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted amino group;
R 2 represents an optionally substituted fluorenyl group, a substituted naphthyl group, or an optionally substituted group represented by any one of the following structures:
R 3 represents 0 to 7 identical or different substituents attached to the naphthyl group; and
X represents a single bond, —CH 2 — group, or —NH— group.
19. The therapeutic agent according to claim 18 , further comprising an active ingredient of at least one additional drug for the treatment of obesity.
20. A method of treating obesity, comprising administering the therapeutic agent according to claim 18 , in combination with at least one additional drug for the treatment of obesity.
21. A method of preparing a medicament for the treatment of obesity, comprising combining a pharmaceutically acceptable carrier and a therapeutic amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1 .
22. A method of treating obesity, comprising administering the compound or a pharmaceutically acceptable salt thereof according to claim 1 to a patient in need thereof.